8 Review of guidance
8.1 The review date for a technology appraisal refers to the month and year in which the Guidance Executive will consider whether the technology should be reviewed. This decision will be taken in the light of information gathered by the Institute, and in consultation with consultees and commentators.
8.2 The guidance on this technology was considered for review in September 2010 at the same time as 'Etanercept and efalizumab for the treatment of adults with psoriasis' (NICE technology appraisal guidance 103) and 'Infliximab for the treatment of adults with psoriasis' (NICE technology appraisal guidance 134). Details are available on the NICE website.